AI Summary
This study compares pembrolizumab and ipilimumab for advanced melanoma, showing that pembrolizumab significantly improves overall survival compared to ipilimumab. The 10-year follow-up data from the phase 3 KEYNOTE-006 study are presented.
Pembrolizumab significantly improved overall survival (OS) versus ipilimumab for unresectable advanced melanoma in KEYNOTE-006 (NCT01866319); 10-year follow-up data are presented.